Curcumin, Indomethacin, and Naproxen Synergistically inhibit the Growth of Human Colorectal Cancer Cells (HT-29): Current Research

Hai-Dan Yuan; Hyun-Jin Kim; Ju-Seop Kang

Hai-Dan Yuan Department of Pharmacology and Clinical Pharmacology Laboratory, College of Medicine, Hanyang University, Seoul 133-791, Korea and College of Pharmacy, Yanbian University, Yanji 133000, Jilin Province, China.
Hyun-Jin Kim Department of Pharmacology and Clinical Pharmacology Laboratory, College of Medicine, Hanyang University, Seoul 133-791, Korea.
Ju-Seop Kang Department of Pharmacology and Clinical Pharmacology Laboratory, College of Medicine, Hanyang University, Seoul 133-791, Korea.

Keywords: Curcumin, indomethacin, naproxen, HT-29, colon cancer

Abstract

The aim of this study was to investigate the effect of curcumin, indomethacin, curcumin and naproxen combination synergistically on the growth of HT-29 cells. The growth of HT-29 cells was examined by MTS cell viability assay by one to four days treatment with curcumin (10?50 ?M), indomethacin (250?1,000 ?M), curcumin (10?50 ?M) and naproxen (250?1,000 ?M) to 20⁴ HT-29 cells/mL. The results suggested that curcumin inhibited the growth of HT-29 cells in a dose-dependent fashion. In concentration range from 500 to 1,000 ?M, indomethacin inhibitied the growth of HT-29 cells in a dose-dependent fashion. To examine inhibitory administered or give of curcumin and indomethacin, curcumin and naproxen combinination on the HT-29 cell lines, we treatment with 20 ?M curcumin and indomethacin (500 ?M, 750 ?M) combinination curcumin and naproxen (750 ?M, 1,000 ?M) combinination to 20⁴ HT-29 cells/well. The results suggested that curcumin potentiates the inhibitory effect of indomethacin on the growth of HT-29 cell lines by shifting the dose-dependent manner.